Phreesia (PHR) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
14 May, 2026Voting matters and shareholder proposals
Election of two Class I directors, Chaim Indig and Jon Kessler, to serve until the 2029 Annual Meeting and until successors are elected and qualified.
Ratification of KPMG LLP as independent registered public accounting firm for the fiscal year ending January 31, 2027.
Advisory vote to approve the compensation of named executive officers as disclosed in the Proxy Statement.
Proxy holders authorized to vote on other matters that may arise during the meeting or its adjournments.
Board of directors and corporate governance
Board recommends voting in favor of all proposals, including director elections and executive compensation.
Executive compensation and say-on-pay
Advisory vote scheduled to approve the compensation of named executive officers.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Phreesia
- Proxy seeks approval for director elections, auditor ratification, and executive pay, highlighting governance and ESG.PHR
Proxy filing14 May 2026 - FY27 revenue guidance lowered on pharma headwinds, but margin and cash flow outlooks remain strong.PHR
Q4 202630 Mar 2026 - 19% revenue growth, positive free cash flow, and improved EBITDA mark a strong Q2 FY25.PHR
Q2 202522 Jan 2026 - Revenue up 17%, net loss narrowed, and Adjusted EBITDA positive with strong outlooks ahead.PHR
Q3 202511 Jan 2026 - Double-digit revenue growth, positive cash flow, and strong 2026 outlook maintained.PHR
Q4 202526 Dec 2025 - Q3 FY2026 saw 13% revenue growth, profitability, and a major acquisition completed.PHR
Q3 20269 Dec 2025 - Annual meeting to vote on directors, auditor, and executive pay, with focus on governance and ESG.PHR
Proxy Filing1 Dec 2025 - Key votes include director elections, auditor ratification, and executive pay approval.PHR
Proxy Filing1 Dec 2025 - Q1 FY2026 revenue up 15%, net loss narrows, EBITDA and free cash flow surge, guidance raised.PHR
Q1 202626 Nov 2025